Tumor abnormality-oriented nanomedicine design
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
[HTML][HTML] Turning cold tumors into hot tumors by improving T-cell infiltration
YT Liu, ZJ Sun - Theranostics, 2021 - ncbi.nlm.nih.gov
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …
Recent advances in hyperthermia therapy‐based synergistic immunotherapy
The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …
Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy
L Huang, Y Li, Y Du, Y Zhang, X Wang, Y Ding… - Nature …, 2019 - nature.com
One of the main challenges for immune checkpoint blockade antibodies lies in malignancies
with limited T-cell responses or immunologically “cold” tumors. Inspired by the capability of …
with limited T-cell responses or immunologically “cold” tumors. Inspired by the capability of …
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
D Shi, X Wu, Y Jian, J Wang, C Huang, S Mo… - Nature …, 2022 - nature.com
Abstract Indoleamine 2, 3 dioxygenase 1 (IDO1) is an attractive target for cancer
immunotherapy. However, IDO1 inhibitors have shown disappointing therapeutic efficacy in …
immunotherapy. However, IDO1 inhibitors have shown disappointing therapeutic efficacy in …
Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection
Radiotherapy (RT), including external beam RT and internal radiation therapy, uses high-
energy ionizing radiation to kill tumor cells. However, ionizing radiation inevitably damages …
energy ionizing radiation to kill tumor cells. However, ionizing radiation inevitably damages …
Clinical development of metabolic inhibitors for oncology
KM Lemberg, SS Gori, T Tsukamoto… - The Journal of …, 2022 - Am Soc Clin Investig
Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …
developed in the 1940s. In the past 25 years, there has been increased recognition of …
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
MO de Olza, BN Rodrigo, S Zimmermann… - The Lancet …, 2020 - thelancet.com
Notable advances have been achieved in the treatment of cancer since the advent of
immunotherapy, and immune checkpoint inhibitors have shown clinical benefit across a …
immunotherapy, and immune checkpoint inhibitors have shown clinical benefit across a …
Targeting the IDO1 pathway in cancer: from bench to bedside
M Liu, X Wang, L Wang, X Ma, Z Gong… - Journal of hematology & …, 2018 - Springer
Abstract Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase
(TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into …
(TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into …
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer
Neoadjuvant chemotherapy (NAC) prior to surgery and immune checkpoint therapy (ICT)
have revolutionized bladder cancer management. However, stratification of patients that …
have revolutionized bladder cancer management. However, stratification of patients that …